Connetics' Extina not approvable

CNCT received a not approvable letter from FDA for Extina 2% ketoconazole foam to treat seborrheic dermatitis. The agency said the

Read the full 217 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE